Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone44-20-3829-6230
Debt
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees126
OptionableNot Optionable
Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions
What is Autolus Therapeutics' stock symbol?
Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."
What price target have analysts set for AUTL?
5 analysts have issued 12 month price targets for Autolus Therapeutics' stock. Their predictions range from $37.00 to $50.00. On average, they expect Autolus Therapeutics' stock price to reach $44.00 in the next year. This suggests a possible upside of 42.3% from the stock's current price. View Analyst Price Targets for Autolus Therapeutics.
What is the consensus analysts' recommendation for Autolus Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Autolus Therapeutics.
What are Wall Street analysts saying about Autolus Therapeutics stock?
Here are some recent quotes from research analysts about Autolus Therapeutics stock:
- 1. According to Zacks Investment Research, "Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. " (1/15/2019)
- 2. HC Wainwright analysts commented, "We envision upside to our target if the upcoming data reflect the anticipated advantages of Autolus’ CAR T assets. Our $45 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model. Our DCF is based on: beta of 1.45, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.2%, and tax rate of 15% beginning in FY 2027." (11/2/2018)
Has Autolus Therapeutics been receiving favorable news coverage?
News coverage about AUTL stock has trended positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Autolus Therapeutics earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the company's share price in the next few days.
Who are some of Autolus Therapeutics' key competitors?
Some companies that are related to Autolus Therapeutics include Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Spark Therapeutics (ONCE), Editas Medicine (EDIT) and Rubius Therapeutics (RUBY).
Who are Autolus Therapeutics' key executives?
Autolus Therapeutics' management team includes the folowing people:
- Dr. Christian Martin Itin, Chairman & CEO (Age 55)
- Dr. Martin Pulé, Founder, Sr. VP & Chief Scientific Officer (Age 47)
- Mr. Andrew J. Oakley, CFO & Sr. VP (Age 57)
- Mr. Christopher Vann, Sr. VP & COO (Age 55)
- Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 54)
When did Autolus Therapeutics IPO?
(AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.
When did the company's lock-up period expire?
Autolus Therapeutics' lock-up period expired on Wednesday, December 19th. Autolus Therapeutics had issued 8,823,530 shares in its public offering on June 22nd. The total size of the offering was $150,000,010 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.
How do I buy shares of Autolus Therapeutics?
Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Autolus Therapeutics' stock price today?
One share of AUTL stock can currently be purchased for approximately $30.93.
How big of a company is Autolus Therapeutics?
Autolus Therapeutics has a market capitalization of $1.24 billion. Autolus Therapeutics employs 126 workers across the globe.
What is Autolus Therapeutics' official website?
How can I contact Autolus Therapeutics?
Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]
MarketBeat Community Rating for Autolus Therapeutics (NASDAQ AUTL)
MarketBeat's community ratings are surveys of what our community members think about Autolus Therapeutics and other stocks. Vote "Outperform" if you believe AUTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
